1. Home
  2. CDNA vs ANAB Comparison

CDNA vs ANAB Comparison

Compare CDNA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$24.08

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$54.32

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
ANAB
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
CDNA
ANAB
Price
$24.08
$54.32
Analyst Decision
Buy
Buy
Analyst Count
6
12
Target Price
$28.00
$71.67
AVG Volume (30 Days)
652.3K
482.8K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
0.05
N/A
Revenue
$48,324,000.00
$234,603,000.00
Revenue This Year
$16.01
N/A
Revenue Next Year
$11.31
$52.14
P/E Ratio
$469.20
N/A
Revenue Growth
18.93
157.01
52 Week Low
$10.96
$17.11
52 Week High
$24.02
$73.30

Technical Indicators

Market Signals
Indicator
CDNA
ANAB
Relative Strength Index (RSI) 65.75 43.43
Support Level $15.80 $53.46
Resistance Level N/A $57.70
Average True Range (ATR) 1.04 2.61
MACD 0.09 -0.14
Stochastic Oscillator 93.00 35.23

Price Performance

Historical Comparison
CDNA
ANAB

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: